←
Stuart Burri, M.D.519 posts
Stuart Burri, M.D. avatar✓

Stuart Burri, M.D. ✓

@stuxrt

Dad, husband, Radiation Oncologist with Southeast Radiation Oncology and Levine Cancer Institute @atriumhealth @levinecancer. Of course, the opinions are mine

◷ Joined May 2011▧ 109 Photos and videos
ASTRO avatar
⟳ Stuart Burri, M.D. retweeted
ASTRO@ASTRO_org·Jul 27

Congratulations to the class of 2026 ASTRO Fellows! ASTRO is pleased to announce that 39 members will receive the ASTRO Fellow (FASTRO) designation. The 2026 class of Fellows will be officially inducted during the Awards Ceremony at ASTRO's 68th Annual Meeting in Boston. #ASTRO26 Learn more: ow.ly/ZVSC50Ztma9

Post attachment
Dan Trifiletti, MD avatar
⟳ Stuart Burri, M.D. retweeted
Dan Trifiletti, MD@DanTrifMD·27 Sep 2025

🔔⏰ Welcome to #ASTRO2025 ⏰ 🔔 Honored to sit on the stage in front of a big crowd while we learn from @ChristyCramerMD @stuxrt @joshuapalmermd If you’re on your way get excited, tons of great presentations planned and networking opportunities. And also perfect weather 💪

0:06
OncoAlert avatar
⟳ Stuart Burri, M.D. retweeted
OncoAlert@OncoAlert·28 Jan 2025

Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer out on Lancet Oncology buff.ly/4huOHek Multicentre, single-arm phase 2 trial evaluated the safety and efficacy of a novel treatment approach for patients with unresectable, locally advanced non-small-cell #LungCancer ( #NSCLC ), involving stereotactic body radiotherapy (SBRT) to the primary tumor, followed by standard chemoradiotherapy to the lymph nodes and consolidation immunotherapy with durvalumab. Sixty-one patients were enrolled, with a median follow-up of 29.5 months. The study reported a 1-year progression-free survival (PFS) of 62.7%, although it did not achieve the primary endpoint of significant improvement over historical controls. Treatment-related grade 3–4 adverse events included decreased neutrophil and white blood cell counts, and treatment-related deaths occurred in 7% of patients. Despite not meeting the primary endpoint, the treatment demonstrated favorable activity and safety profiles, forming the basis for an ongoing randomized phase 3 trial (NRG Oncology LU008). @DrJRadOnc @KMilehamMD @DrChrisCorso @AKesarwala @stuxrt Ping OncoAlert Rad Onc Faculty @MKnoll_MD @HenningWillers @fumikochino @_ShankarSiva @PercyLeeMD @Icro_Meattini @DrChowdharyMD @DrLesterColl @ErinGillespieMD @seanmmcbride @NiuSanford #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

Post attachment